BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests- 6 Objections for an Ocean side Wedding
- Figure out How to Streamline Your Profits in Gold Speculation
- Canada's Friendly Sunshine Coast City Is An Outdoor Playground Perfect For Hiking And Paddling
- Pick Your Favored sort of cooking
- Emotional wellness Matters: My Fight with Tension
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- Israel says it will keep control over part of southern Lebanon after war with Hezbollah ends
- Iran steps up executions as experts warn state killing being used to suppress political dissent
